Metabolic syndrome and dairy product consumption: Where do we stand?

被引:6
|
作者
Sebedio, Jean-Louis [1 ,2 ]
Malpuech-Brugere, Corinne [1 ,2 ,3 ]
机构
[1] CRNH Auvergne, UNH, INRA, UMR 1019, F-63000 Clermont Ferrand, France
[2] Univ Auvergne, Clermont Univ, Lab Nutr Humaine, Unite Nutr Humaine, BP 321,58 Rue Montalembert, F-63009 Clermont Ferrand 1, France
[3] CRNH Auvergne, F-63000 Clermont Ferrand, France
关键词
Dairy products; Metabolic syndrome; Foodomics; Metabolomics; Cohorts; Human intervention; DOSE-RESPONSE METAANALYSIS; TRANS-PALMITOLEIC ACID; PENTADECANOIC ACID; RISK-FACTORS; MILK-FAT; HEALTH; BIOMARKERS; PEPTIDES; QUALITY; MARKER;
D O I
10.1016/j.foodres.2016.03.040
中图分类号
TS2 [食品工业];
学科分类号
0832 ;
摘要
Shifts in food composition and in dietary pattern as well as a modification in physical activity have led to increasing prevalence of overweight and obesity. Obesity is often accompanied by a cluster of metabolic abnormalities, termed the metabolic syndrome. Milk is an essential component of the human diet, and several dairy products resulting from processing of milk such as cheese, yogurt and dairy desserts are being consumed by millions of people worldwide. Consequently many studies were carried out on dairy products and their effect on body weight and fat, diabetes, metabolic syndrome (MetS), cardiovascular health, and bone health. Many epidemiological studies and a few meta-analyses on the relation between dairy product consumption and risk of metabolic syndrome were recently conducted using observational studies published up to March 2015. The evaluation of dairy consumption was carried out using food frequency questionnaires, food records and 24-h recall for most of the analyses so far published. As a general conclusion of the recent data, one may suggest an inverse relation between the consumption of dairy products and the prevalence of metabolic syndrome. However, it is still not very clear if all the dairy products have the same effects. Metabolomic technologies using targeted approaches have been used to unravel the identity of potential biomarkers of dairy product consumption. Some potential biomarkers such as fatty acids (15:0, 17:0, trans 16:1n - 7) have been proposed to evaluate dairy product consumption. However, recently published papers raised concerns about using these fatty acids as potential biomarkers of dairy fat/dairy product intake. On the contrary, little has been published using metabolomic approaches on the potential metabolic effects of dairy products or on the relation between their consumption and the prevalence of metabolic syndrome or the associated pathologies. (C) 2016 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1077 / 1084
页数:8
相关论文
共 50 条
  • [1] Metabolic syndrome and HCV: Where do we stand in 2010?
    Lamb P.
    Harrison S.
    [J]. Current Hepatitis Reports, 2010, 9 (3) : 133 - 139
  • [2] Impact of dairy components addition on metabolic and microbiota programming: where do we stand?
    Lemaire, Marion
    [J]. JOURNAL OF THE AMERICAN OIL CHEMISTS SOCIETY, 2021, 98 : 231 - 231
  • [3] Dairy product consumption and the metabolic syndrome
    Abedini, Marzieh
    Falahi, Ebrahim
    Roosta, Sajjad
    [J]. DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2015, 9 (01) : 34 - 37
  • [4] Dairy product consumption and the metabolic syndrome
    van Meijl, Leonie E. C.
    Vrolix, Ruth
    Mensink, Ronald P.
    [J]. NUTRITION RESEARCH REVIEWS, 2008, 21 (02) : 148 - 157
  • [5] Millet Production and Consumption in India: Where Do We Stand and Where Do We Go?
    Asha Devi Sukumaran Sreekala
    P. Anbukkani
    Alka Singh
    B. Dayakar Rao
    Girish K. Jha
    [J]. National Academy Science Letters, 2023, 46 : 65 - 70
  • [6] Millet Production and Consumption in India: Where Do We Stand and Where Do We Go?
    Sukumaran Sreekala, Asha Devi
    Anbukkani, P.
    Singh, Alka
    Dayakar Rao, B.
    Jha, Girish K.
    [J]. NATIONAL ACADEMY SCIENCE LETTERS-INDIA, 2023, 46 (01): : 65 - 70
  • [7] Metabolomics and Metabolic Diseases: Where Do We Stand?
    Newgard, Christopher B.
    [J]. CELL METABOLISM, 2017, 25 (01) : 43 - 56
  • [8] The metabolic syndrome: Where are we and where do we go?
    Roth, JL
    Mobarhan, S
    Clohisy, M
    [J]. NUTRITION REVIEWS, 2002, 60 (10) : 335 - 337
  • [9] ANTIPHOSPHOLIPID SYNDROME AND EPILEPSY: WHERE DO WE STAND?
    Noureldine, M. A.
    Harifi, G.
    Haydar, A. A.
    Berjawi, A.
    Nader, M.
    Elnawar, R.
    Sweid, A.
    Al Saleh, J.
    Khamashta, M. A.
    Uthman, I.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 1072 - 1072
  • [10] Behcet's syndrome: Where do we stand?
    Yazici, H
    [J]. AMERICAN JOURNAL OF MEDICINE, 2002, 112 (01): : 75 - 76